Aktis Oncology Inc. (AKTS), a clinical-stage oncology company, is scheduled to present clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting solid tumors in metastatic prostate cancer, at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) on May 30, 2026.
AKY-2519 is a novel, miniprotein radioconjugate targeting B7-H3 in solid tumors, including those in prostate and lung cancers. It contains the Actinium-225 (225Ac) alpha-emitting radioisotope that targets specific expressing tumors, facilitating anti-tumor activity by increasing penetration, internalization, and retention in cancer cells.
The data to be presented will include the normal tissue biodistribution and tumor uptake assessments of AKY-2519, evaluated through PET/CT imaging, and tumor dosimetry analyses by sequential SPECT/CT imaging. The imaging to determine the action of AKY-2519 was conducted in Germany and South Africa, on patients with metastatic castration-resistant prostate cancer (mCRPC).
The U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for AKY-2519 in March, and the company plans to begin a Phase 1b trial by mid-2026.
AKTS closed Tuesday at $20.50, down 1.58%.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.